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Abstract
Background: Typhoid fever is an acute, invasive, and potentially fatal systemic infection caused by Salmonella
enterica subspecies enterica serotype Typhi (S. Typhi). Drug resistance to antimicrobials such as ciprofloxacin is
emerging in developing countries, threatening the efficacy of treatment of patients in endemic regions as well as
of travellers returning from these countries.
Methods: We compared the antimicrobial resistance profiles of 192 S. Typhi isolated from patients over a time span
of twelve years. Susceptibility testing was done by the disk diffusion method. A representative selection of isolates
(n = 41) was screened by PCR for mutations in the quinolone resistance-determining regions (QRDRs) of the gyrA
and parC genes and all 192 isolates were screened for plasmid-mediated quinolone resistance (PMQR) genes.
Multilocus sequence typing (MLST) was used to investigate the sequence type of isolates from patients with a
known history of international travel.
Results: Resistance rates for nalidixic acid increased from 20 % to 66.7 % between 2002 and 2013. Resistance to
ciprofloxacin was detected in 55.6 % of the isolates by 2013. Ciprofloxacin resistance was predominantly associated
with the triple substitutions Ser83→ Phe and Asp87→ Asn in GyrA and Ser80→ Ile in ParC. The plasmid-mediated
resistance gene qnrS1 was detected in two isolates. Sequence type ST1 was associated with the Indian subcontinent,
while ST2 was distributed internationally. Multidrug resistance was noted for 11.5 % of the isolates.
Conclusions: Fluoroquinolone resistant S. Typhi constitute a serious public health concern in endemic areas as well as
in industrialized countries. Increased surveillance of global patterns of antimicrobial resistance is necessary and the
control of resistant strains is of the utmost importance to maintain treatment options.
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Background
Salmonella enterica subspecies enterica serovar Typhi
(S. Typhi) is a human-specific etiological agent of an
acute, invasive, and potentially fatal systemic infection
also known as typhoid fever [1]. The disease is a serious
public health problem in developing countries with the
Indian subcontinent (India, Pakistan, Afghanistan, Nepal
and Bangladesh) representing a geographic area of intense
disease activity [2]. In industrialized countries typhoid
fever is rare and mainly associated with travel to high-risk
destinations [3, 4]. In the 1990ies, antimicrobial therapy
became problematic in endemic areas due to multi-drug
resistant (MDR) S. Typhi, rendering chloramphenicol, tri-
methoprim and ampicillin, which were the drugs used as
first-line treatment ineffective. Currently, fluoroquinolones
such as ciprofloxacin are recommended by the WHO [5],
as they are the most effective orally active, inexpensive
and well-tolerated drugs for the treatment of typhoid fever
[6]. Hence, the worrisome signs of increasing resistance to
this class of antimicrobials represent a challenge for
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effective control and management of typhoid fever, es-
pecially in endemic countries. Resistance is mainly due
to the accumulation of mutations in the quinolone
resistance-determining regions (QRDRs) of DNA gyrase
and topoisomerase IV genes (target site alterations).
Additionally, plasmid-mediated quinolone resistance
(PMQR) confer a form of reduced susceptibility which
is thought to promote the accumulation of the target
site mutations [7]. PMQR include the Qnr families of
pentapeptide repeat proteins encoded by qnrA, qnrB,
qnrC qnrD and qnrS, [8, 9] and [10]. The majority of
mutations in quinolone resistant S. Typhi have been de-
tected within the quinolone resistance-determining re-
gion (QRDR) of the DNA gyrase gene gyrA and in the
topoisomerase gene parC [11]. Primary mutations in
target site genes generate resistance to the quinolone
antimicrobial nalidixic acid, making it useful as a surro-
gate marker of decreased susceptibility to fluoroquino-
lones [12], as resistance to nalidixic acid correlates with
decreased susceptibility to ciprofloxacin and hence to
potential treatment failure [13–15].
The aim of this study was to describe the antimicrobial
susceptibility profiles of S. Typhi isolated from patients
over a time span of twelve years. In a selection of iso-
lates, the presence of point mutations in the genes gyrA
and parC that encode the quinolone targets was deter-
mined. The clonal relationship of isolates known to be
associated with international travel was assessed.
Methods
Clinical isolates
Between 2002 and 2013, 203 S. Typhi isolates were sent
to the National Centre for Enteropathogenic Bacteria
and Listeria (NENT), Switzerland, for final serological
identification and strain collection. All samples had been
submitted by hospitals or primary diagnostic laboratories
located in Switzerland. The number of collected strains
varied from 10 to 24 per annum, with a median of 16.
Patients’ data was anonymized. Studies performed with
such strains had previously been declared unobjection-
able by the ethics commission of the Canton of Zürich,
Switzerland (declaration KEK Stv.-Nr. 19/12). For the
study, only one isolate per patient was selected. Isolates
from family members were considered separate samples
(10 samples from 4 families). Of the 203 collected iso-
lates, 192 met these criteria for further analysis.
Antimicrobial susceptibility tests
Susceptibility testing was performed for the 192 isolates
using the Kirby Bauer disk diffusion method and the an-
timicrobials nalidixic acid, ciprofloxacin, ampicillin,
amoxicillin/clavulanic acid, cephalotin, cefotaxime, gen-
tamicin, kanamycin, streptomycin, tetracycline, sulfa-
methoxazole, trimethoprim and chloramphenicol
(Becton Dickinson, Heidelberg, Germany). Results were
interpreted according to the Clinical and Laboratory
Standards Institute (CLSI) [16]. Hereby, breakpoints for
ciprofloxacin are ≥31 mm (susceptible), 21–30 mm
(intermediate) and ≤20 mm (resistant).
Multidrug-resistance (MDR) was defined as resistance to
conventional antityphoid drugs ampicillin, trimethoprim-
sulfamethoxazole and chloramphenicol (13).
Molecular characterization of quinolone resistance genes
DNA was extracted using a standard heat lysis protocol.
In brief, 5 bacterial colonies were resuspended in 450 μl
lysis buffer containing 0.1 M Tris pH 8.5, 0.05 % Tween-
20 and 240 μg/ml proteinase K. Samples were incubated
at 60 °C for 60′, followed by 97 °C for 15′. Lysates were
centrifuged for 10″ at 13,200 rpm and 5 μl of the super-
natant were used for PCR.
A subset of 41 isolates eliciting various resistance pat-
terns and representing different years of isolation was
subjected to PCR-based detection of mutations in the
quinolone resistance-determining regions (QRDRs) of
the gyrA and parC genes, using amplification primers
described previously [17]. All 192 isolates were screened
for plasmid-mediated quinolone resistance (PMQR)
genes using primers described previously for qnrA
[17, 18], qnrB [19], qnrC [20], qnrD [21], and qnrS [17].
Custom sequencing was performed by Microsynth (Bal-
gach, Switzerland) and nucleotide sequences were ana-
lysed with CLC Main Workbench 6.6.1. For database
searches the BLASTN program of NCBI (http://
www.ncbi.nlm.nih.gov/blast/) was used.
Multilocus sequence typing
Multilocus sequence typing (MLST) [22] was used to in-
vestigate the sequence type of 26 isolates from patients
with a known history of international travel. These iso-
lates were randomly selected from 83 travel-associated
isolates. Internal fragments of the seven housekeeping
genes aroC, dnaN, hemD, hisD, purE, sucA and thrA
were amplified by PCR. Sequencing of the amplification
products was performed by Microsynth (Balgach). Se-
quence types (ST) were assigned in accordance with the
Salmonella enterica MLST Database http://mlst.ucc.ie/
mlst/dbs/Senterica.
Results and discussion
A detailed overview of the 192 S. Typhi isolates analysed
in this study, together with anamnestic data and any
travel information of the patients is given in Additional
file 1: Table S1. The majority of the strains (96 %) were
isolated from blood or stool. Patient median age was
26 years (range <1–74 years), ninety-five (49.5 %) were
female and 21.4 % were children (<16 years). Informa-
tion on the travel background was availabe for 83
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patients. Thereof, the three main countries involved
were India with 41 patients (49.4 %), Pakistan with 7
(8.4 %) and Bangladesh with 4 (4.8 %) patients.
The rate of full susceptibility of S. Typhi to the antimi-
crobials tested in this study declined from 80 % in 2002
to 28 % in 2013. This decrease was mainly due to the
emergence of isolates with resistance to nalidixic acid,
with resistance rates increasing from 20 to 66.7 % during
the same period. Ciprofloxacin resistance rose from 0 to
55.6 %, albeit variably (Table 1). Multidrug-resistance
(MDR), and especially resistance to former drugs of first
choice ampicillin, trimethoprim-sulfamethoxazole and
chloramphenicol [13], was observed variably (0–25 %,
Table 1). Resistance to ampicillin-clavulanic acid and
cephalotin was found in one and 8 isolates, respectively,
while streptomycin and tetracycline resistance was de-
tected in 24 (12.5 %) and 15 (7.8 %) isolates, respectively
(Additional file 1: Table S1).
In total, 113 (58.9 %) of the isolates were resistant to
nalidixic acid. Of the 36 analysed nalidixic acid-resistant
isolates, 35 (97 %) contained a substitution in Ser83 of
GyrA, whereby 27 (75 %) contained the amino acid substi-
tution Ser83→ Phe and the remaining 8 carried the muta-
tion Ser83→Tyr (Table 2). Only one nalidixic acid and
ciprofloxacin resistant isolate (N10-1839, see Additional
file 1: Table S1) tested negative for substitutions in GyrA.
This clearly illustrates the predominance of gyrA muta-
tions in quinolone resistant S. Typhi.
In total, 39 (20.3 %) of the isolates were resistant to
ciprofloxacin. The first ciprofloxacin-resistant strain
from the collection described in this study was isolated
in 2004 from a traveller from Cambodia (isolate 1736–
04) and was associated with a Ser83→ Phe in GyrA and
a zone diameter of 19 mm in the disk diffusion test for
ciprofloxacin (Additional file 1: Table S1 and Table 2).
One ciprofloxacin-resistant isolate contained an additional
Glu84→Gly substitution in ParC (isolate 1715–06, see
Additional file 1: Table S1). In the disk diffusion test, this
substitution was associated with a zone diameter of
14 mm (Table 2). One further isolate (1751–08) contained
a Glu84→ Lys substitution in ParC. This substitution has
been described previously in two ciprofloxacin-resistant iso-
lates from Bangladesh [23]. However, those isolates both
contained the two additional substitutions Trp106→Gly
and Tyr128→Asp in ParC. Since isolate 1751–08 was cate-
gorized as intermediately susceptible to ciprofloxacin (zone
diameter 21 mm), the Glu84→ Lys substitution in ParC
does not appear to be crucial for ciprofloxacin resistance.
Ciprofloxacin-resistant strains isolated since 2010
(n = 23) all contained the combination of Ser83→ Phe
and Asp87→Asn in GyrA as well as the Ser80→ Ile sub-
stitution in ParC and were associated with decreased zone
Table 1 Number and proportion (%) of nalidixic acid-,
ciprofloxacin- and multidrug-resistant Salmonella Typhi isolated
between 2002 and 2013
Resistance pattern
Total no. of isolates NAL CIP MDRa
Year no. (%) no. (%) no. (%)
10 2002 2 (20) 0 (0) 0 (0)
16 2003 6 (37.5) 0 (0) 2 (12.5)
13 2004 5 (38.5) 1 (7.7) 2 (15.4)
16 2005 5 (31.3) 3 (18.8) 1 (6.3)
16 2006 9 (56.3) 3 (18.8) 0 (0)
18 2007 15 (83.3) 5 (27.8) 3 (16.7)
16 2008 9 (56.3) 3 (18.8) 3 (18.8)
18 2009 14 (77.8) 1 (5.6) 1 (5.6)
24 2010 20 (83.3) 6 (25) 4 (16.7)
15 2011 9 (60) 4 (26.7) 3 (20)
12 2012 7 (58.3) 3 (25) 3 (25)
18 2013 12 (66.7) 10 (55.6) 0 (0)
Total
192 113 (58.9) 39 (20.3) 22 (11.5)
Abbreviations: NAL, nalidixic acid; CIP, ciprofloxacin; MDR, multidrug resistant
aMultidrug resistance is defined as resistance to ampicillin, trimethoprim/
sulfamethoxazole and chloramphenicol (13)
Table 2 Mutations in QRDR of GyrA and ParC observed in 35 nalidixic acid- and/or ciprofloxacin-resistant S. Typhi isolated between
2002 and 2013 and corresponding zone diameters obtained by the disk diffusion test for ciprofloxacin
Mutation
No. of isolates (%) GyrA ParC No. of CIP resistant isolates
(zone diameters [mm])a
Years of
isolation
Identified associated country
(no. of isolates)
8 (22.9) Ser83→ Tyr 4 (20) 2002–2009 India (2), Bangladesh (1)
18 (51.4) Ser83→ Phe 5 (19–21) 2003–2011 India (2), Pakistan (3),
Bangladesh (1), Cambodia (1)
1 (2.9) Ser83→ Phe Glu84→ Gly 1 (14) 2006 India (1)
1 (2.9) Ser83→ Phe Glu84→ Lys 0 (21) 2008 India (1)
7 (20) Ser83→ Phe / Asp87→ Asn Ser80→ Ile 7 (6–11) 2010–2013 India (2), Nepal (1)
Abbreviation: CIP, ciprofloxacin
aBreakpoints for ciprofloxacin according to CLSI guidelines (16): susceptible, ≥30 mm; intermediate, 21–30 mm; resistant, ≤20 mm
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diameters of 6–11 mm in the disk diffusion tests for cipro-
floxacin (Table 2). This genotype appears to be becoming
more frequent compared to previous reports [11]. Al-
though no gyrB or parE gene mutations were analysed in
this study, the data presented here indicate these particu-
lar substitutions in GyrA and ParC may be considered a
major quinolone resistance mechanism in S. Typhi. Muta-
tions in gyrA are recognized to be predominant in nali-
dixic acid resistant S. Typhi [24, 25]. Increased efflux
pump-mediated mechanisms, which are observed in other
fluoroquinolone-resistant Salmonella [26], have very re-
cently been reported to be absent in S. Typhi [27], further
highlighting the importance of target-site mutations. Fur-
thermore, a recent study by Baker et al. [24] has shown
that mutations in the target genes gyrA and parC correlate
with an increase of intrinsic fitness in S. Typhi. This indi-
cates that the quinolone resistance genotypes observed in
our study may continue to circulate even in the absence of
antimicrobial selective pressure.
The plasmid-mediated quinolone resistance gene
qnrS1 was found in a fully susceptible isolate from 2009
and in a ciprofloxacin-resistant isolate from 2010 (isolates
N09-2035 and N10-2349, respectively, see Additional file 1:
Table S1). No other PMQR genes were detected in any of
the isolates. There are few studies that describe PMQR
genes in S. Typhi and our findings indicate that they may
play a minor role in quinolone resistance of S. Typhi. The
qnrS gene has to our knowledge been reported once in an
isolate from the Democratic Republic of the Congo [28],
whereas in quinolone-resistant S. Typhi isolates from
India the qnrB gene predominates [29].
On account of travel histories, 54 isolates (28 %) were
demonstrably associated with the Indian subcontinent
(Additional file 1: Table S1). However, this number is pos-
sibly understated, due to missing travel information for
many of the patients. This highlights the need to improve
travel history reporting within the healthcare system in
order to get a more precise picture of the association of
distinct strains with distinct regions worldwide. Multilocus
sequence typing of S. Typhi is limited by the fact that it
discriminates 2 sequence types only. Nevertheless, typing
assigned 15 isolates to ST1, of which 12 (80 %) were asso-
ciated with the Indian subcontinent. By contrast, the ori-
gins of the 14 isolates assigned to ST2 were more widely
dispersed and included Southeast Asia (4 isolates; 28.6 %),
Africa (3 isolates; 21.4 %), Mexico (4 isolates; 29 %) and
South America (1 isolate; 7.1 %). This finding is consistent
with observations of Dahiya et al. [30] and indicates that
ST2 may be circulating internationally, while ST1 mainly
persists in the Indian subcontinent.
Conclusions
This study presents an overview over the development
of antimicrobial resistance profiles of S. Typhi over the
last 12 years and provides molecular characteristics of
nalidixic acid- and ciprofloxacin-resistant S. Typhi iso-
lated in that time span. Since fluoroquinolones are cur-
rently the mainstay of the treatment of typhoid fever,
resistance in S. Typhi threatens to limit therapeutic op-
tions and constitutes a serious public health concern in
endemic areas as well as in industrialized countries. In-
creased surveillance of global patterns of antimicrobial re-
sistance is necessary and the control of resistant strains is
of the utmost importance.
This study adds to the current knowledge about the
global circulation of quinolone-resistant S. Typhi and
their associated mechanisms of resistance.
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